Photodynamic therapy (PDT) is gaining a measure of increased clinical acceptance as an intervention in several malignant and non-malignant conditions (Marcus, 1992; Furuse et al., 1993) . The recent Canadian and Dutch limited approvals of the porphyrin photosensitiser Photofring's are evidence of this trend. While a major emphasis in PDT research has been and continues to be the development of new photosensitisers that overcome some of Photofrins'g inherent limitations (Gomer, 1991) , it is likely that Photofring will remain in widespread use for some time. It is therefore important to continue efforts directed at the optimisation of Photofrin'-sensitised PDT. Although Photofrin' absorbs light throughout the visible spectrum, typical treatment regimens include irradiation at or near 630 nm, which corresponds to the longest wavelength absorption band of this photosensitiser. This is done in order to take advantage of increased optical penetration in tissue. However, there are clinically relevant situations in which this deeper optical penetration is neither necessary nor desirable. In treating relatively thin lesions that reside at the surface of otherwise healthy tissue, the more rapid attenuation of shorter wavelength light offers the possible advantage of improving the therapeutic ratio. This consideration is of high importance in the case of the oesophagus, for example, where perforation of the wall is potentially catastrophic.
Haematoporphyrin derivative (HpD)-and Photofrinmsensitised PDT have been performed by other investigators using the 514 nm output of the argon-ion laser in preclinical (Bellnier et al., 1985; van Gemert et al., 1985; Tochner et al., 1986; Nseyo et al., 1993) and clinical (DeLaney et al., 1993) settings. These studies have demonstrated the potential of 514 nm irradiation to induce tumour necrosis at depths of 2-3 mm. The purpose of the present study was to extend this earlier work and to identify criteria for a somewhat more quantitative dosimetry at this treatment wavelength. Our goal was to establish treatment conditions at 514 nm that produced long-term delays in the regrowth of human mesothelioma xenografts that were similar to those that had been previously reported using 630 nm irradiation (Gibson et al., 1994 (Gibson et al., 1990a) . Results of the 514 nm PDT treatment protocols were compared with data obtained using 630 nm irradiation (50 mW cm-2, 2 h), a subset of which was previously published (Gibson et al., 1994) .
Statistical analysis
The tumour volume doubling times that resulted from the various treatment protocols were compared using the logrank test. This test is commonly used to analyse time-to-event (e.g. survival) data in clinical research (Dawson-Saunders and Trapp, 1994 Comparisons between the various 514 nm treatment groups and the benchmark 630 nm group revealed that the mesothelioma response to the red light, 50 mW cm-2 treatment was significantly better than it was to three of the four green light protocols. Tumour regrowth following 630 nm irradiation was delayed significantly longer than it was in response to continuous 514 nm irradiation at 20 mW cm-2 or 28 mW cm-2 and following the stepped 20:40 irradiation. In each of these three comparisons, the Pvalues returned by the log-rank analysis were <0.006. In contrast, the response of the mesothelioma xenografts to the 20:28 irradiation could not be distinguished statistically from that of the 630 nm treatment group. The various statistical intercomparisons are presented in Table II . (Gibson et al., 1990b; Cincotta et al., 1994) and in the mesothelioma xenograft (Gibson et al., 1994) . In these systems, a given optical energy density produced significantly longer tumour volume doubling times when the fluence rate was reduced over the range 200-50 mW cm-2. In the initial design of our 514 nm treatment protocols, we therefore sought to equate the rate at which photons were absorbed by the photosensitiser with the corresponding rate at 630 nm. It is important to emphasise that matching the rate of photon absorption is quite different from matching the incident energy fluence rate. Since significant long-term tumour response in the Photofrin®-sensitised mesothelioma xenografts had been accomplished with 630 nm irradiation using a treatment fluence rate of 50 mW cm-2 and a total fluence of 360 J cm-2, we established these as the basis for our comparison. Matching the rate of photon absorption for two treatment wavelengths requires correction for the photosensitiser extinction coefficients and for the difference in photon energies at the two wavelengths. The Photofrin' extinction is approximately three times greater at 514 nm than it is at 630 nm (Moan and Sommer, 1984; Bellnier et al., 1985) , and the ratio of photon energies (514:630) is approximately 1.22, which means that at a given energy fluence rate, the photon fluence rate at 514 nm is reduced with respect to that at 630 nm by this factor. These two considerations combine such that, in order to equate the rates of photon absorption by Photofring, the energy fluence rate at 514 nm must be reduced by a factor of 2.5 relative to 630 nm. Thus, a 50 mW cm-2 incident fluence rate at 630 nm is approximately equivalent to 20 mW cm-2 at 514 nm in terms of the rate of photon absorption, and this was the basis for selection of 20 mW cm-2 as one of our 514 nm treatment intensities. From measurements performed using thin sections of HpD-sensitised murine bladder tumour tissue, Bellnier et al. (1985) reported the ratio of extinction coefficients (514:630) to be 2.18. This value was the basis for the 28 mW cm-2 514 nm irradiation protocol.
However, these considerations do not take into account the increased optical attenuation of the shorter wavelength light in tissue. Although we do not have quantitative optical absorption and scattering coefficients for this tumour at these wavelengths, it is certain that the 514 nm light is more rapidly attenuated. Thus, although it is possible to match rates of photon absorption for two wavelengths at a single depth in the tumour, for example, at the surface, the more rapid attenuation of the green light creates a situation in which it is not possible to match rates of absorption simultaneously throughout the tumour volume. If one chooses to increase the incident intensity at 514 nm in order to attempt to match the fluence rate at some depth within the tumour, then the tissue that is more proximal to the incident beam will be subjected to a fluence rate that is higher than optimal, and the therapeutic efficacy will be compromised.
This predicament suggests a new strategy that increases or steps the fluence rate as the PDT irradiation proceeds. Initially, a low fluence rate (,<20 mW cm-2) should be used to optimally treat the most superficial region. As the treatment continues and a threshold dose is achieved near the surface, the incident fluence rate should be increased to effectively administer photodynamic dose to the deeper tumour regions. It was this rationale that led us to implement the stepped 20:28 and 20:40 irradiation regimens. Statistical analysis of the mesothelioma responses to these stepped regimens shows that irradiation with 40 mW cm-2 during the second half of the treatment is significantly less effective than with 28 mW cm-2. This finding is consistent with previously reported results obtained with Photofringsensitised mesothelioma xenografts and 630 nm irradiation, where relatively lower fluence rates were found to be more effective (Gibson et al., 1994) . Our interpretation of these data is that rapid photochemical oxygen consumption at higher irradiation fluence rates creates regions of transient hypoxia within which singlet oxygen formation is reduced (Foster et al., 1991) . We are encouraged by the similar responses of the mesothelioma xenografts to the 20:28 green and the 50 mW cm-2 red light protocols, however, our approach to the design of the stepped irradiation schemes at the shorter wavelength was somewhat empirical, and more work needs to be done in order to develop treatment strategies that are based on real knowledge of tumour optical properties in vivo.
Attention to the factors governing green light dosimetry for PDT underscores an elementary aspect of photochemistry that has been overlooked in some published experimental designs. Photodynamic dose derives from photons that are absorbed by the photosensitiser and not simply from the total optical energy density deposited in a tissue volume. This can be readily seen if one compares these quantities for the cases that we have treated in this report. Assuming that the similar therapeutic outcomes in response to the 50 mW cm-2 red light and 20:28 green light treatments are the result of approximately equal photodynamic doses in the mesothelioma xenografts, it follows that these treatments produced similar spatial distributions of absorbed photons. However, the optical energy densities deposited in the tissue were appreciably different in these two cases. The 2 h, 630 nm irradiation resulted in a total fluence of 360 J cm-2, whereas the 20:28, 514 nm irradiation of the same duration resulted in Another factor that must be considered in intracavity PDT such as is performed in the bladder is the influence of the integrating sphere effect and its wavelength dependence. As discussed by Van Staveren et al. (1994) and by Star et al. (1987) , the increased diffuse intensity arising from multiple scattering events in the wall of the cavity has the effect of increasing the uniformity of irradiation over the surface of the bladder and of alleviating the sensitivity to optical fibre position. Van Staveren et al. (1994) have suggested that the magnitude of the integrating sphere effect is appreciably reduced at 532 nm with respect to its value at 630 nm, aud these authors concluded that on this basis 630 nm irradiation would be prefereable to 532 nm in whole bladder PDT. Wavelength-dependent absorption and scattering coefficients presented and discussed in that report indicate that absorption decreases and scattering increases in bladder tissue as the wavelength is lowered from 532 to 514 nm, and it is possible that the resulting increase in the diffuse fluence at 514 nm would be enough to provide a sufficient integrating sphere effect. However, this is clearly an aspect of green light dosimetry that requires more careful evaluation.
In summary, we have demonstrated a 514 nm irradiation regimen that produces long-term tumour control in a mesothelioma xenograft model that is statistically indistinguishable from that observed previously using 630 nm light. On the basis of our experience, we suggest that for carcinoma in situ and for lesions that are 2 mm or less in thickness, the incident energy fluence rate at 514 nm should be approximately 20 mW cm-2 or less. For thicker lesions, stepped irradiation protocols that increase the incident fluence rate as therapy progresses may be optimal and should be explored further in other tumour systems. The clinical opportunities for using green light in Photofrinl-sensitised PDT to optimise therapeutic ratio should be considered.
